JP4932730B2 - バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 - Google Patents

バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 Download PDF

Info

Publication number
JP4932730B2
JP4932730B2 JP2007543471A JP2007543471A JP4932730B2 JP 4932730 B2 JP4932730 B2 JP 4932730B2 JP 2007543471 A JP2007543471 A JP 2007543471A JP 2007543471 A JP2007543471 A JP 2007543471A JP 4932730 B2 JP4932730 B2 JP 4932730B2
Authority
JP
Japan
Prior art keywords
alkyl
indazol
dihydro
chromen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007543471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008532925A5 (https=
JP2008532925A (ja
Inventor
ゴムツヤン，アーサー・アール
バイバート，エロル・ケイ
シユミツト，ロバート・ジー・ジユニア
リー，チー−ハン
ブラウン，エス・ブライアン
ジンカーソン，ケイ・タミー
コーニツグ，アール・ジヨン
ダーネン，エフ・ジエローム
ラツシヨウ，ステイーブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2008532925A publication Critical patent/JP2008532925A/ja
Publication of JP2008532925A5 publication Critical patent/JP2008532925A5/ja
Application granted granted Critical
Publication of JP4932730B2 publication Critical patent/JP4932730B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007543471A 2004-11-24 2005-11-22 バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 Expired - Fee Related JP4932730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63063604P 2004-11-24 2004-11-24
US60/630,636 2004-11-24
PCT/US2005/042545 WO2006065484A2 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012003232A Division JP2012111766A (ja) 2004-11-24 2012-01-11 バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2008532925A JP2008532925A (ja) 2008-08-21
JP2008532925A5 JP2008532925A5 (https=) 2008-10-23
JP4932730B2 true JP4932730B2 (ja) 2012-05-16

Family

ID=36588346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007543471A Expired - Fee Related JP4932730B2 (ja) 2004-11-24 2005-11-22 バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
JP2012003232A Pending JP2012111766A (ja) 2004-11-24 2012-01-11 バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012003232A Pending JP2012111766A (ja) 2004-11-24 2012-01-11 バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用

Country Status (13)

Country Link
US (2) US7812019B2 (https=)
EP (2) EP2527339A1 (https=)
JP (2) JP4932730B2 (https=)
KR (2) KR101250824B1 (https=)
CN (2) CN102161653A (https=)
AU (1) AU2005316972B2 (https=)
BR (1) BRPI0518581A2 (https=)
CA (1) CA2588909A1 (https=)
IL (1) IL183321A0 (https=)
MX (1) MX2007006205A (https=)
NZ (1) NZ555318A (https=)
TW (1) TW200633712A (https=)
WO (1) WO2006065484A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012111766A (ja) * 2004-11-24 2012-06-14 Abbott Lab バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2347921C2 (ru) * 2004-03-02 2009-02-27 Роузмаунт Инк. Технологическое устройство с усовершенствованным обеспечением электропитанием
US8538560B2 (en) 2004-04-29 2013-09-17 Rosemount Inc. Wireless power and communication unit for process field devices
US8145180B2 (en) * 2004-05-21 2012-03-27 Rosemount Inc. Power generation for process devices
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
WO2006116165A1 (en) 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
CN101365684A (zh) * 2005-10-28 2009-02-11 艾博特公司 抑制trpv1受体的吲唑衍生物
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2012778A4 (en) * 2006-04-18 2011-08-10 Abbott Lab VANILLOID RECEPTOR (VR1) SUBType 1 ANTAGONISTS AND USES THEREOF
US7913566B2 (en) 2006-05-23 2011-03-29 Rosemount Inc. Industrial process device utilizing magnetic induction
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
CA2672196A1 (en) * 2006-12-20 2008-07-03 Abbott Laboratories Antagonists of the trpv1 receptor and uses thereof
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US8250924B2 (en) 2008-04-22 2012-08-28 Rosemount Inc. Industrial process device utilizing piezoelectric transducer
CN102067048B (zh) * 2008-06-17 2017-03-08 罗斯蒙特公司 用于具有可变压降的现场设备的rf适配器
US8694060B2 (en) 2008-06-17 2014-04-08 Rosemount Inc. Form factor and electromagnetic interference protection for process device wireless adapters
US8929948B2 (en) 2008-06-17 2015-01-06 Rosemount Inc. Wireless communication adapter for field devices
CN102084307B (zh) 2008-06-17 2014-10-29 罗斯蒙特公司 用于具有低压本质安全钳的现场设备的rf适配器
WO2010023512A1 (en) * 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
AR073631A1 (es) * 2008-10-17 2010-11-17 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor
MX2011004090A (es) * 2008-10-17 2011-05-31 Abbott Lab Antagonistas trpv1.
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN101654435B (zh) * 2009-06-09 2014-01-29 沈阳药科大学 N-苯甲基喹啉羧酸类化合物、组合物及其制备方法
US20100318007A1 (en) * 2009-06-10 2010-12-16 O'brien Donald J Electromechanical tactile stimulation devices and methods
US9674976B2 (en) 2009-06-16 2017-06-06 Rosemount Inc. Wireless process communication adapter with improved encapsulation
US8626087B2 (en) 2009-06-16 2014-01-07 Rosemount Inc. Wire harness for field devices used in a hazardous locations
IN2012DN01983A (https=) 2009-08-24 2015-07-24 Ascepion Pharmaceuticals Inc
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
US10761524B2 (en) 2010-08-12 2020-09-01 Rosemount Inc. Wireless adapter with process diagnostics
EP2688866A1 (en) 2011-03-25 2014-01-29 AbbVie Inc. Trpv1 antagonists
US9310794B2 (en) 2011-10-27 2016-04-12 Rosemount Inc. Power supply for industrial process field device
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CN109574972A (zh) * 2018-07-13 2019-04-05 郑州大学 一种3-烷基取代-4-色满酮类化合物及其制备方法
IL301691A (en) * 2020-09-30 2023-05-01 Univ Leuven Kath 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer
CN120398870A (zh) * 2024-01-31 2025-08-01 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839A2 (en) * 1989-03-08 1990-09-12 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
JPH06293748A (ja) * 1992-09-11 1994-10-21 E R Squibb & Sons Inc アリールウレア（チオウレア）およびシアノグアニジン誘導体
JP2000516958A (ja) * 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
JP2003514808A (ja) * 1999-11-16 2003-04-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての尿素誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8900565A (nl) 1989-03-08 1990-10-01 Philips Nv Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode.
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
EP1601665A2 (en) 2003-03-07 2005-12-07 Glaxo Group Limited Urea derivatives
NZ555318A (en) * 2004-11-24 2011-01-28 Abbott Lab Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
CN101365684A (zh) * 2005-10-28 2009-02-11 艾博特公司 抑制trpv1受体的吲唑衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839A2 (en) * 1989-03-08 1990-09-12 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
JPH06293748A (ja) * 1992-09-11 1994-10-21 E R Squibb & Sons Inc アリールウレア（チオウレア）およびシアノグアニジン誘導体
JP2000516958A (ja) * 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
JP2003514808A (ja) * 1999-11-16 2003-04-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての尿素誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012111766A (ja) * 2004-11-24 2012-06-14 Abbott Lab バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用

Also Published As

Publication number Publication date
CA2588909A1 (en) 2006-06-22
US7812019B2 (en) 2010-10-12
EP1844038A2 (en) 2007-10-17
KR20120137420A (ko) 2012-12-20
WO2006065484A3 (en) 2009-02-19
US8440691B2 (en) 2013-05-14
JP2012111766A (ja) 2012-06-14
KR101250824B1 (ko) 2013-04-05
AU2005316972A1 (en) 2006-06-22
US20060128689A1 (en) 2006-06-15
CN102161653A (zh) 2011-08-24
EP2527339A1 (en) 2012-11-28
MX2007006205A (es) 2009-02-13
AU2005316972B2 (en) 2011-11-10
IL183321A0 (en) 2008-04-13
KR20070086607A (ko) 2007-08-27
US20110152250A1 (en) 2011-06-23
CN101443327A (zh) 2009-05-27
WO2006065484A2 (en) 2006-06-22
JP2008532925A (ja) 2008-08-21
TW200633712A (en) 2006-10-01
NZ555318A (en) 2011-01-28
BRPI0518581A2 (pt) 2008-11-25

Similar Documents

Publication Publication Date Title
JP4932730B2 (ja) バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
EP2855467B1 (en) Processes to produce certain 2-(pyridine-3-yl)thiazoles
US7622493B2 (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
US8350083B2 (en) Antagonists of the TRPV1 receptor and uses thereof
US7015233B2 (en) Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
JP4862042B2 (ja) バニロイド受容体サブタイプ１（ｖｒ１）のアンタゴニスト及びその使用
JP2009513659A (ja) Ｔｒｐｖ１受容体を阻害するインダゾール誘導体
JP2012121887A (ja) バニロイド受容体サブタイプ１（ｖｒ１）に対するアンタゴニストとして作用するベンズイソチアゾール−１，１−ジオキシドおよびこれらの使用
JP2008523154A (ja) ６−［（５ｓ，９ｒ）−９−（４−シアノフェニル）−３−（３，５−ジクロロフェニル）−１−メチル−２，４−ジオキソ−１，３，７−トリアザスピロ［４．４］ノン−７−イル］ニコチン酸の結晶形
HK1169980A (en) Antagonists of the trpv1 receptor and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120215

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150224

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees